| NCT06723171 | Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis | NOT_YET_RECRUITING | PHASE2 | 2025-06 | 2026-04 | 2026-03 |
| NCT05280314 | Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors | RECRUITING | PHASE2 | 2023-12-21 | 2027-01 | 2025-04-30 |
| NCT05155254 | IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-05-17 | 2027-09 | 2025-05-30 |
| NCT05077709 | IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-02-14 | 2024-11-30 | 2024-01-04 |
| NCT03562871 | IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC | COMPLETED | PHASE1, PHASE2 | 2018-08-22 | 2022-04-12 | 2021-02-06 |
| NCT02991651 | Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC | TERMINATED | PHASE1 | 2016-12-07 | 2025-05-09 | 2025-05-09 |
| NCT02438215 | Study of IRX4204 for Treatment of Early Parkinson's Disease | COMPLETED | PHASE1 | 2014-08 | 2015-05 | 2015-05 |
| NCT01540071 | Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer | COMPLETED | PHASE2 | 2011-08 | 2015-12 | 2015-12 |